Skip to main content

Market Overview

Ovid Shares Rally On Soticlestat Development Pact With Takeda In Rare Epilepsy Syndromes


Takeda Pharmaceutical Co Ltd (NYSSE: TAK) has agreed to secure global rights from Ovid Therapeutics Inc (NASDAQ: OVID) for soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic encephalopathies, including Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS).

  • Under this new agreement, Takeda will develop and commercialize soticlestat globally, and Ovid will no longer have any financial obligation to Takeda under the original collaboration agreement announced in 2017.
  • Ovid will receive an upfront payment of $196 million and is eligible to receive up to an additional milestone payment of $660 million.
  • Also, Ovid will receive tiered royalties beginning in the low double-digits and up to 20% on sales of soticlestat.
  • Data from the Phase 2 ELEKTRA study showed that soticlestat met its primary endpoint of reducing seizure frequency in pediatric patients with DS or LGS.
  • Takeda plans to start Phase 3 studies of soticlestat in children and young adults with DS and LGS in Q2 2021.
  • Soticlestat is an inhibitor of the enzyme cholesterol 24-hydroxylase (CH24H), with the potential to reduce seizure susceptibility and improve seizure control.
  • CH24H is expressed in the brain, where it converts cholesterol into 24S-hydroxycholesterol (24HC) to adjust the homeostatic balance of brain cholesterol.
  • Ovid will hold a conference call and webcast today at 8:30 a.m. EST.
  • Price Action: OVID shares are trading higher by 48% at $4.37on the last check Wednesday.

Related Articles (TKPHF + TAK)

View Comments and Join the Discussion!

Posted-In: Dravet SyndromeBiotech News Penny Stocks Health Care Contracts FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at